好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Atogepant on Migraine Headache Severity for the Preventive Treatment of Episodic Migraine: A Post-Hoc Analysis of the 12-Week ADVANCE and 52-Week Open-Label Trials
Headache
P9 - Poster Session 9 (11:45 AM-12:45 PM)
12-003
Evaluate the impact of atogepant 60mg once daily (QD) on migraine headache day severity in participants with episodic migraine (EM).
Atogepant is an oral, calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine. 
This post hoc analysis included participants with EM from the phase 3, randomized, double blind, placebo-controlled, 12-week ADVANCE trial and phase 3, randomized, 52-week, open-label trial. Outcomes included change from baseline in the number of monthly moderate/severe migraine headache days and change from baseline in mean pain severity of migraine headache days, including resolved days. If the number of monthly migraine days at a post-baseline period was reduced from baseline, a pain severity score of 0 was imputed for any resolved migraine headache days.
The modified intent-to-treat population included participants from ADVANCE (placebo, N=214; atogepant 60mg QD, N=222) and the open-label trial (atogepant 60mg QD, N=520). At Weeks 9–12 in ADVANCE, the number of monthly moderate/severe migraine headache days was reduced by 64% with atogepant compared to baseline (vs. 43% reduction with placebo), and the change from baseline in mean pain severity of migraine headache days, including resolved days, was -1.46 for atogepant and -0.97 for placebo. In the open-label trial, the number of monthly moderate/severe migraine headache days was reduced by 57% at Weeks 1–4 compared to baseline, which improved to a 78% reduction at Weeks 49–52 compared to baseline. The change from baseline in mean pain severity of migraine headache days, including resolved days, was -1.30 at Weeks 1–4 and decreased to -1.73 at Weeks 49–52. Atogepant was safe and well tolerated in both trials.
Atogepant reduced the number of monthly moderate/severe migraine headache days and mean pain severity of migraine headache days compared with placebo in ADVANCE, and reductions were consistent across 52 weeks in the open-label trial. 
Authors/Disclosures
Umer Najib, MD, FAAN (West Virginia University Hospitals)
PRESENTER 		Dr. Najib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Najib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck . Dr. Najib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie . The institution of Dr. Najib has received research support from Eli Lilly. The institution of Dr. Najib has received research support from Abbvie.
Belinda A. Savage-Edwards, MD, FAAN (Rehabilitation & Neurological Services) The institution of Dr. Savage-Edwards has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Llly. The institution of Dr. Savage-Edwards has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Easai. The institution of Dr. Savage-Edwards has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilly. The institution of Dr. Savage-Edwards has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Association of Neurology Journal. Dr. Savage-Edwards has or had stock in Eli Lilly.Dr. Savage-Edwards has or had stock in AbbVie. The institution of Dr. Savage-Edwards has received research support from Eli LIlly Co.. The institution of Dr. Savage-Edwards has received research support from AbbVie. The institution of Dr. Savage-Edwards has received research support from IQVIA.
Teshamae Monteith, MD, FAAN (University of Miami) Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for American Headache Society . Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Monteith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cephalalgia. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for New England Journal of Medicine JW. The institution of Dr. Monteith has received research support from AbbVie. The institution of Dr. Monteith has received research support from lilly. The institution of Dr. Monteith has received research support from Ipsen. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a 好色先生 with Medscape. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a 好色先生 with Massachusetts Medical Society . Dr. Monteith has a non-compensated relationship as a President Elect with Florida Society of Neurology that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Editorial Board /Board Member with American Migraine Foundation that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Board Member with International Headache Society that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Pfizer that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Abbvie that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Theranica that is relevant to AAN interests or activities.
Hsiangkuo Yuan, MD, PhD (Jefferson Headache Center) An immediate family member of Dr. Yuan has received personal compensation for serving as an employee of Merck. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Yuan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Salvia. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerenovous. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Regional Anesthesia and Pain Medicine. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Headache and Pain Reports. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cephalalgia. The institution of Dr. Yuan has received research support from NIH. The institution of Dr. Yuan has received research support from American Headache Society. The institution of Dr. Yuan has received research support from Pfizer. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Invited speaker with Chinese Stroke Association.
Yingyi Liu (AbbVie) Yingyi Liu has received personal compensation for serving as an employee of AbbVie.
Natty Chalermpalanupap, PhD (AbbVie) Dr. Chalermpalanupap has received personal compensation for serving as an employee of AbbVie. Dr. Chalermpalanupap has stock in AbbVie.
Ivonna Reda, PharmD (N/A) Mrs. Reda has received personal compensation for serving as an employee of Abbvie. Mrs. Reda has stock in Abbvie.
Brett Dabruzzo, PharmD (AbbVie Medical Affairs) Dr. Dabruzzo has received personal compensation for serving as an employee of AbbVie. Dr. Dabruzzo has stock in AbbVie.
Jessica Ailani, MD, FAAN (Medstar Georgetown Neurology) Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspya. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kallyope. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Self Magazine. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. The institution of Dr. Ailani has received research support from Lundbeck. The institution of Dr. Ailani has received research support from Merz. The institution of Dr. Ailani has received research support from Pfizer. Dr. Ailani has received research support from Mi-Helper. The institution of Dr. Ailani has received research support from ShiraTronic. Dr. Ailani has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to AAN interests or activities.